Revenue Breakdown
Composition ()
No data
Revenue Streams
Soligenix Inc (SNGX) generates its revenue primarily from Specialized BioTherapeutics, which accounts for 100.0% of total sales, equivalent to $2.34K. Understanding this concentration is critical for investors evaluating how SNGX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Comparative Benchmarking
In the context of the broader market, SNGX competes directly with industry leaders such as COCP and AEON. With a market capitalization of $13.21M, it holds a significant position in the sector. When comparing efficiency, SNGX's gross margin of N/A stands against COCP's N/A and AEON's N/A. Such benchmarking helps identify whether Soligenix Inc is trading at a premium or discount relative to its financial performance.
